dc05f01
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 8, 2022 (NCT06873542)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- FascinINHIBITOR
FSCN1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06873555 | Phase 1/Phase 2 (Phase 2) | Sep 11, 2024 | Heronova Pharmaceuticals |
| NCT06873542 | Phase 1 | Jul 8, 2022 | Heronova Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Heronova Pharmaceuticals | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1